PTO/SB/08A (8/03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Substitute for form 1449/PTO **COMPLETE IF KNOWN Application Number** 10/057,288 Filing Date 01/25/2002 INFORMATION DISCLOSURE First Named Inventor CHRISTIAN LARSEN STATEMENT BY APPLICANT(S) Art Unit 1644 (use as many sheets as necessary) **Examiner Name** GAMBEL, PHILLIP Sheet Attorney Docket Number D0136 NP of **U.S. PATENT DOCUMENTS** Cite Publication date Name of Patentee or Pages, Columns, Lines, Where Relevant Examiner **Document Number** MM-DD-YYYY Applicant of Cited Document Passages or Relevant Figures Appear Initials No. FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, Check box if English Examiner **Publication Date** Name of Patentee or Where Relevant Passages language translation is Cite No. Foreign Patent Document MM-DD-YYYY Applicant of Cited Document Initials or Relevant Figures Appear attached AA WO2000/40270 07/13/2000 **PCT**

Examiner Date
Signature Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

PTO/SB/08B (8/03)
Approved for use through 07/31/2006. OMB 0651-0031
Frademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S) (use as many sheets as necessary)

2

Sheet 2 of

| 5.6. I atent and trademark office, 5.5. DET ANTINENT OF COMMENCE | | | | |
|--|------------------|--|--|--|
| COMPLETE IF KNOWN | | | | |
| Application Number | 10/057,288 | | | |
| Filing Date | 01/25/2002 | | | |
| First Named Inventor | CHRISTIAN LARSEN | | | |
| Art Unit | 1644 | | | |
| Examiner Name | GAMBEL, PHILLIP | | | |
| Attorney Docket Number | D0136 NP | | | |
| | | | | |

| | | NON PATENT LITERATURE DOCUMENTS | |
|----------------------|-------------|--|--|
| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | Check box if English language Translation is attached |
| | 2AA | Gomez, L. et al., "Treatment of Omenn syndrome by bone marrow transplantation", The Journal of Pediatrics, Vol. 127(1), pp. 76-81 (1995) | |
| | 2AB | Ito, T. et al., "Long-term acceptance of major histocompatibility complex-mismatched lung allografts induced by mixed chimerism", Sapporo Medical Journal, Vol. 66(6), pp. 317-326 (1997) | |
| | 2AC | Jabado, N. et al., "Treatment of familial hemophagocytic lymphohisticcytosis with bone marrow transplantation from HLA genetically nonidentical donors", Blood, Vol. 90(12), pp. 4743-8 (1997) | |
| | 2AD | Judge, T.A. et al., "The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival", Journal of Immunology, Vol. 162(4), pp. 1947-51 (1999) | |
| | 2AE | Kapelushnik, J. et al., "Fludarabine-based protocol for haploidentical peripheral blood stem cell transplantation in Hurler syndrome", Journal of Pediatric hematology/oncology: official journal of the American Society of Pediatric Hematology/Oncology, Vol. 22(5), pp. 433-436 (2000) | |
| | 2AF | Tanaka, J. et al., "T-cell co-signalling molecules in graft-versus-host disease", Annals of hematology, Vol. 79(6), pp. 283-90 (2000) | |
| | 2AG | Walters, M.C. et al., "Bone marrow transplantation for sickle cell disease", New England Journal of Medicine, Vol. 335(6), pp. 369-376 (1996) | Marie de la companya del companya de la companya de la companya del companya de la companya de l |
| | 2AH | Zheng, X.X. et al., "CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment", Journal of Immunology, Vol. 162(8), pp. 4983-4990 (1999) | |
| | | | |
| | | | |

| Examiner | Date | |
|-----------|------------|--|
| Signature | Considered | |